ERICA Study: Preventing Nausea and Vomiting Associated with Novel HER2 ADC Treatment
Click the blue text above to follow us Editor’s Note: Novel HER2 antibody-drug conjugates (ADCs) have profoundly changed the clinical practice of breast cancer treatment, and managing their adverse reactions is a concern for clinicians. Although nausea and vomiting caused by novel HER2 ADCs in clinical trials are mostly mild adverse events, current international guidelines … Read more